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Abstract
Background: Cancer of the esophagus is a deadly malignancy, and development of biomarkers
that predict survival is an urgent need. The apoptotic pathways have been hypothesized as
important in progression of esophageal squamous cell carcinoma (ESCC). We investigated a panel
of proteins that regulate apoptosis as candidate of biomarkers of prognosis in ESCC.
Methods: Tissue microarray (TMA) including 313 surgically-resected cases of ESCC specimens
was built for immunohistochemical interrogation. We evaluated seven genes in the FasL-Fas
apoptotic pathway - FasL, Fas, FAS-associated death domain protein (FADD), phosphorylated-
FADD, and caspase 8 and 10, and the antiapoptotic protein bcl-2. We studied pathway integrity
and relations to risk and clinical factors, and determined the prognostic significance of each marker.
Results: Five markers showed strong inter-marker correlations (r ≥ 0.28, p < 0.001), including
FasL, Fas, FADD, and caspases 8 and 10. FasL and FADD also showed modest correlations with
one or more cancer risk factors, but none of the markers was significantly associated with either
tumor stage or lymph node metastasis, the only two clinical factors that predicted survival in these
ESCC cases. Multivariate-adjusted proportional hazard regression models showed no association
between protein expression and risk of death for any of the seven markers examined.
Conclusion: Individual biomarkers in the apoptosis pathway do not appear to predict survival of
patients with ESCC.
Background
Fas-mediated apoptosis is thought to be involved in the
initiation and development of esophageal squamous cell
carcinoma (ESCC). Previous gene expression profiling of
ESCC showed over-expression of FAS-associated death
domain RNA (FADD) and under-expression of Fas and
caspase 8 [1]. The phosphorylated form of FADD (p-
FADD) has recently been reported to regulate apoptotic
activity [2]. Although the role of p-FADD in ESCC out-
come is unclear, higher levels of p-FADD protein corre-
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lated with reduced survival in patients with lung
adenocarcinomas [3] and prostate cancer [4].
Using an ESCC tissue microarray (TMA) [5], we explored
the expression of FasL, Fas, FADD, p-FADD, caspase 8 and
10, which are proteins involved in the FasL-Fas apoptotic
pathway, and the antiapoptotic protein bcl-2. We deter-
mined the prevalence of protein expression for each
marker, investigated pathway integrity by evaluating the
correlations between individual markers as well as
between markers and risk factors/clinico-pathologic fea-
tures, and we examined the prognostic significance of the
markers on the survival of ESCC cases.
Methods
Patient selection
This study was approved by the Institutional Review
Boards of the Shanxi Cancer Hospital and the U.S.
National Cancer Institute. Patients presenting to the
Shanxi Cancer Hospital in Taiyuan, Shanxi, People's
Republic of China between 1996 and 2001 were eligible
for inclusion in this study. The Shanxi Cancer Hospital,
the largest cancer hospital in Shanxi, performed surgery
on approximately 2000 new esophageal annually during
the study period. We included cases in this study who: (i)
were males or females 20 years of age or older, (ii) had
newly diagnosed (incident) cancer of the esophagus with-
out previous treatment (including surgery, chemotherapy,
or radiotherapy), (iii) underwent surgical resection of
their tumor at the Shanxi Cancer Hospital, and (iv) had
their diagnosis histologically confirmed. Since a primary
objective of this study was to evaluate somatic changes in
tumors, we limited recruitment to patients who had com-
plete surgical resection of their tumor as their primary
therapy; approximately 50% of new ESCC cases under-
went surgical resection as their primary therapy. Neoadju-
vant and adjuvant therapy were not employed at the
Shanxi Cancer Hospital in surgically resected ESCC cases
during the time period that this study was conducted.
Esophageal cancer cases were limited to those with histo-
logical ESCC, which included nearly all esophageal can-
cers since adenocarcinoma of the esophagus is essentially
nonexistent in this high-risk population. All histological
diagnoses were made initially by pathologists at the
Shanxi Cancer Hospital and confirmed by pathologists at
the National Cancer Institute. In addition to confirmation
of their histologic diagnosis, cases were classified as either
well differentiated or poorly differentiated ESCC.
We collected information on demographic and lifestyle
cancer risk factors [eg, smoking, alcohol drinking, family
history of upper gastrointestinal (UGI) cancer] on cases
using a structured interview with a questionnaire admin-
istered by a nurse in the hospital prior to surgery. Clinical
data was abstracted from hospital records after surgery.
Demographic, lifestyle and clinical data for cases included
in this study are shown in Table 1. All patients (or their
family members) were re-contacted in 2003 to ascertain
vital status.
Tissue microarray (TMA) construction
Details of the TMA construction were previously described
[5]. In brief, the TMA was constructed with surgical resec-
tion tissue samples from 313 ESCC cases, and selected
Table 1: Characteristics of patients in apoptosis biomarker protein expression tissue microarray study
Risk factor Prevalence of risk factor or clinicopathologic feature
(N = 265)
Gender (male) 0.66
Age (years, median) 58
Tobacco use (yes) 0.60
Alcohol use (daily or weekly) 0.22
Family history of upper gastrointestinal cancer (yes) 0.27
Clinico-pathologic feature
Tumor grade
I 0.17
II 0.60
III 0.23
IV 0.004
Tumor stage
1 0.004
2 0.13
3 0.86
4 0.01
Lymph node metastasis (yes) 0.45
Degree differentiation (poor) 0.47BMC Cancer 2009, 9:310 http://www.biomedcentral.com/1471-2407/9/310
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control tissues using 0.6 mm needles. After exclusion of
cores with inadequate tissue following sectioning and tis-
sue transfer, the final immunohistochemical analyses
included cores from 265 ESCC cases. Each of the 265 dif-
ferent ESCC cases contributed to one or more of the dif-
ferent biomarker analyses. Final numbers of cases for each
of the biomarkers evaluated here are shown in Table 2.
Immunohistochemistry staining and assessment
The TMA sections were stained with antibodies to FasL
(Lab Vision Corp., CA), Fas (Santa Cruz, CA), FADD
(Novocastra, UK), p-FADD (Cell Signaling Technology,
MA), caspase 8 (Lab Vision Corp., CA), caspase 10 (Cell
Signaling Technology, MA), and bcl-2 (Dako, CA). Slides
were stained according to manufacturer's protocols. The
immunohistochemical staining patterns were validated
against previously described patterns of staining for each
marker on a separate TMA, including appropriate positive
and negative controls. Internal positive and negative con-
trols, including normal squamous epithelium of the
esophagus from non-cancer patients were utilized as
available to further support the staining patterns.
Fas and FasL was expressed exclusively in cell membranes,
whereas immunoreactivity of FADD and bcl-2 was cyto-
plasmic. Caspase 8 and 10 expression was detected in
both cytoplasm and nucleus. p-FADD was primarily
expressed in the nucleus of cells. Staining results were
scored based on: (i) percent of positive tumor cells in
tumor tissue: zero (0%), 1 (1-25%), 2 (26-50%), 3 (51-
75%) and 4 (76-100%); and (ii) signal intensity: zero (no
signal), 1 (weak), 2 (moderate) and 3 (marked). An over-
all score was calculated by multiplying the percent cells
positive score by the intensity score (range zero to 12).
Statistical analysis
All statistical analyses were performed using Statistical
Analysis Systems (SAS) (SAS Corp, NC). Spearman corre-
lation coefficients were used to assess associations
between the seven different apoptosis biomarkers, and
between the seven markers and risk factors/clinico-patho-
Table 2: Distribution of protein expression of the apoptotic and antiapoptotic markers, Cox proportional hazard ratios (HR) and 95% 
confidence intervals (CI) for overall survival by the biomarker status for ESCC patients.
Gene protein N1 Distribution of protein expression by overall score (N, prevalence)2 HR3
(95% CI)
P-value
Number 
(prevalence) 
with positive 
protein 
expression 
score4
HR5
(95% CI)
P-value
Score
01234689 1 2
FasL 244 15
(0.06)
48
(0.20)
92
(0.38)
80
(0.33)
3
(0.01)
6
(0.03)
--- --- --- 1.10
(0.95-1.27)
0.45
9 (0.04) 1.04
(0.45-2.40)
0.92
Fas 244 24
(0.10)
49
(0.20)
44
(0.18)
91
(0.37)
8
(0.03)
22
(0.09)
--- 5
(0.02)
1
(0.00)
0.95
(0.87-1.04)
0.07
36 (0.15) 0.79
(0.49-1.27)
0.32
FADD 248 10
(0.04)
122
(0.49)
72
(0.29)
8
(0.03)
17
(0.07)
12
(0.05)
4
(0.02)
1
(0.00)
2
(0.01)
1.05
(0.96-1.14)
0.79
36 (0.15) 1.22
(0.77-1.92)
0.39
pFADD 247 190
(0.77)
48
(0.19)
9
(0.04)
--- --- --- --- --- --- 1.02
(0.76-1.38)
0.25
0 (0.00) ---
Caspase 8 244 11
(0.05)
76
(0.31)
144
(0.59)
--- 11
(0.05)
2
(0.01)
--- --- --- 0.92
(0.76-1.11)
0.53
13 (0.05) 1.03
(0.51-2.05)
0.94
Caspase 10 235 6
(0.03)
47
(0.20)
161
(0.69)
--- 17
(0.07)
3
(0.01)
--- 1
(0.00)
--- 1.07
(0.93-1.23)
0.46
21 (0.09) 1.36
(0.81-2.27)
0.25
Bcl2 253 23
(0.09)
167
(0.66)
58
(0.23)
--- 5
(0.02)
--- --- --- --- 1.01
(0.81-1.27)
0.63
5 (0.02) 1.29
(0.52-3.25)
0.58
1N shown is for each individual biomarker and is less than 265 total because none of 7 biomarkers had data for all 265 ESCC cases.
2Overall score calculated as (intensity score) times (percent cells positive score) as described in methods.
3HR = hazard ratio (95% confidence interval) for increase in score of one category; from multivariate Cox proportional hazards model, adjusted for 
gender, age, tobacco use, alcohol use, family history of UGI cancer, tumor grade, tumor stage, metastasis, and degree differentiation.
4Positive protein expression = overall score ≥ 4 (negative = overall score ≤ 3).
5HR = hazard ratio (95% confidence interval) for positive protein expression (versus negative); from multivariate Cox proportional hazards model, 
adjusted for gender, age, tobacco use, alcohol use, family history of UGI cancer, tumor grade, tumor stage, metastasis, and degree differentiation.BMC Cancer 2009, 9:310 http://www.biomedcentral.com/1471-2407/9/310
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logic features. Overall survival time was calculated as the
date of surgery to the date of death or the date last known
alive. Survival was examined graphically with Kaplan-
Meier curves and analyzed statistically with log-rank tests
and proportional hazards regression models (SAS PHREG
procedure) adjusted for lifestyle and tumor characteristics
as covariates as previously described [6]. All P-values were
two-sided and considered statistically significant if P  <
0.05.
Results
Overall protein expression for the seven markers evalu-
ated here showed low levels of positivity, ranging from
zero to 15% positive (Table 2). The Spearman correlation
coefficients revealed that expression of FasL and Fas, FasL
and caspase 10, FADD and caspase 8, FADD and caspase
10, and caspases 8 and 10 in ESCC were strongly associ-
ated (r ≥ 0.28, p < 0.0001). Fas and caspase 8, and Fas and
caspase 10 were also significantly correlated (r = 0.18, p <
0.01). Moreover, FasL and FADD, FasL and caspase 8, and
caspase 10 and bcl-2 were mildly associated (r = 0.15 to
0.16, p < 0.05) (Table 3).
We successfully contacted 261 of 265 ESCC cases or their
families during follow-up for vital status; 181 cases died
and 80 were still alive at the end of follow-up. Median
overall survival was 677 days (one year, 10 months) and
15 cases were still alive five or more years post-surgery; the
longest survivor was still alive six years and two months
after surgery. Kaplan-Meier graphs and log-rank analyses
of individual markers did not reveal differences in overall
survival by protein expression positivity (data not
shown). Analyses adjusted for demographic attributes
and potential confounding factors in Cox proportional
hazard regression models also failed to identify significant
associations between markers and survival time (Table 2).
Table 4 shows the Spearman correlations between the
seven apoptosis biomarkers and five risk factors, which
include sex, age, tobacco use, alcohol use and family his-
tory of upper gastrointestinal cancer. Significant associa-
tions were observed between FasL expression and male
sex (r = 0.17), tobacco use (r = 0.17), and family history
of UGI cancer (r = -0.18) (all p values < 0.01). Mild corre-
lation was seen between caspase 8 expression and alcohol
use, but it did not reach statistical significance. The Spear-
man correlation between the seven apoptosis biomarkers
and four clinico-pathologic features were also studied
(Table 4). Histological differentiation was strongly corre-
lated with Fas, caspase 10, and bcl-2 expressions (r = -0.26
to -0.36, all p values < 0.0001); lower (but still statistically
significant) correlations were observed with FADD, cas-
pase 8, and FasL. In addition, significant associations were
also seen for tumor grade with Fas, FADD, and caspase 10,
and for tumor stage with Fas expression.
Relations to survival adjusted for these five risk factors and
four clinico-pathologic features are shown in Table 5.
Higher tumor stage [hazard ratio (HR), 1.92; 95% confi-
dence interval (95% CI), 1.14-3.23] and presence of
lymph node metastasis (HR, 2.17; 95% CI 1.59-2.95)
were significantly and independently associated with
death.
Discussion
The results of correlation analyses confirmed that these
biomarkers in the FasL-Fas apoptotic pathway were
closely related. The expression of p-FADD was generally
low in this study, and it may explain why we did not
detect correlations between p-FADD and other markers.
Bcl-2 inhibits BAX (Bcl-2-associated X protein)/BAK (Bcl-
2-antagonist/killer1) proteins, which induce the permea-
bilization of the outer mitochondrial membrane, a crucial
step for apoptotic cell death [7]. Caspase 8 is involved in
functions related to bcl-2 and BAX/BAK proteins. Bcl-2
was not significantly correlated with caspase 8, but was
mildly associated with caspase 10. Although caspase 10
does not seem to directly interact with bcl-2 in the apop-
Table 3: Spearman correlations between 7 apoptosis biomarkers1
FasL Fas FADD pFADD Caspase8 Caspase10 Bcl2
FasL 1.00 0.30*** 0.16* -0.05 0.15* 0.29*** 0.07
Fas 1.00 0.10 -0.04 0.18** 0.18** 0.00
FADD 1.00 -0.05 0.28*** 0.29*** 0.08
phospho-FADD 1.00 0.01 -0.04 0.03
Caspase8 1.00 0.29*** 0.03
Caspase10 1.00 0.15*
Bcl2 1.00
1N varies from 231 to 244 and is less than 265 total because none of 7 biomarkers had data for all 265 ESCC cases
* p < 0.05
** p < 0.01
*** p < 0.0001BMC Cancer 2009, 9:310 http://www.biomedcentral.com/1471-2407/9/310
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tosis pathway, correlation of expression may be antici-
pated, given the complexity of apoptosis regulation.
In accord with our findings, Xue et al. also previously
reported that Fas and FasL were not related to disease-free
survival in ESCC [8]. In contrast, Kase et al. observed sig-
nificantly longer ESCC-free survival in patients with Fas-
positive (versus Fas-negative) tumors, and in FasL-nega-
tive (versus FasL-positive) tumors [9]. Shibakita et al.
reported that Fas expression was an independent prognos-
ticator for recurrence-free survival, but that FasL expres-
sion did not influence ESCC survival.[9] Studies of the
prognostic significance of caspase 8 are limited to a single
previous report in which no effect on survival was noted
[10]. There are no published studies thus far on the prog-
nostic significance of caspase 10 in ESCC.
FADD did not predict survival in ESCC in our study, a
finding similar to that of Chang et al [11]. In contrast, Xue
et al. reported that FADD expression correlated with
decreased survival in ESCC [8]. Induction of p-FADD
results in suppression of cancer cell growth and invasion
through reduction in the non-phosphorylated form in
prostate cancer [12]. Consistent with two previous
reports, we also were unable to relate bcl-2 expression to
prognosis [13,14]. Chang et al. found that bcl-2 expres-
sion correlated with better survival, and was an independ-
ent prognostic factor after multivariate analysis[11].
Similar findings were noted by Parenti et al. and Ohbu et
al., however, in both studies bcl-2 was not an independent
prognostic value after adjustment for other variables in
multivariate analysis [15,16].
FasL expression showed significant correlation with three
risk factors including male sex, tobacco use, and family
history of UGI cancer (Table 4). Fas had mild association
with family history of UGI cancer. Interaction of Fas and
FasL initiates Fas-mediated apoptosis and transmits sig-
Table 4: Spearman correlations between 7 apoptosis biomarkers and 5 risk factors and 4 clinico-pathologic features1
FasL Fas FADD pFADD Caspase8 Caspase10 Bcl2
Risk factors
Male (yes) 0.17** 0.01 0.05 0.02 -0.02 0.03 0.00
Age (yrs) -0.01 0.02 -0.06 -0.05 0.10 0.00 0.00
Tobacco use (yes) 0.17** 0.05 0.08 -0.07 0.00 0.10 0.02
Alcohol use (daily or weekly) 0.00 -0.02 0.20** -0.09 0.13* 0.09 0.02
Family history UGI cancer (yes) -0.18** -0.15* 0.00 0.04 -0.05 0.02 -0.01
Clinico-pathologic features
Tumor grade (I -- IV) -0.10 -0.20** -0.18** 0.08 -0.07 -0.19** 0.02
Tumor stage (1 -- 4) 0.00 -0.14* -0.05 0.10 0.01 0.03 0.03
Lymph node metastasis (yes) 0.02 0.01 -0.04 0.06 0.00 0.01 0.02
Degree differentiation (poor) -0.15* -0.26*** -0.21** 0.03 -0.17** -0.36*** -0.30***
1 N varies from 235 to 253 and is less than 265 total because none of 7 biomarkers had data for all 265 ESCC cases
* p < 0.05
** p < 0.01
*** p < 0.0001
Table 5: Adjusted hazard ratiosa for death by risk factors and clinico-pathologic features in ESCC cases (N = 260)
Variable Hazard Ratio 95% CI P-value
Gender (male) 1.09 0.70 - 1.70 0.69
Age (years) 1.01 0.99 - 1.03 0.28
Tobacco use (yes) 1.08 0.70 - 1.67 0.72
Alcohol use (daily or weekly) 1.00 0.67 -- 1.47 0.98
Family history of UGI cancer (yes) 1.00 0.72 - 1.40 1.00
Tumor grade (I -- IV) 1.18 0.90 - 1.54 0.24
Tumor stage (1 -- 4) 1.92 1.14 - 3.23 0.01
Metastasis (yes) 2.17 1.59 - 2.95 < 0.0001
Degree differentiation (poor) 1.07 0.76 - 1.50 0.71
aModel includes all 9 variables shown (gender, age, tobacco use, alcohol use, family history of UGI cancer, tumor grade, tumor stage, metastasis, 
degree differentiation)BMC Cancer 2009, 9:310 http://www.biomedcentral.com/1471-2407/9/310
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nals to the downstream of the pathway. It suggests that
these risk factors might closely relate to Fas-mediated
apoptosis pathway and contribute to the pathogenesis of
ESCC. Among the clinico-pathologic features we studied
(Table 4), tumor grade was significantly associated with
Fas, FADD and caspase 10. Histological differentiation of
ESCC was significantly correlated with the target biomar-
kers except p-FADD, which exhibited very low expression.
In the present study, we used a TMA to analyze a larger
number of ESCC cases for apoptotic pathway markers
than any previous report in the literature. Further, per-
formance of IHC on a single slide under identical condi-
tions should minimize variability in staining and thus
enhance the reliability of our results. Despite the size and
other favorable characteristics of the current study, the
prevalence of protein positivity for the apoptosis pathway
markers examined was low (≤ 15%) and the differences in
survival between protein expression positive versus nega-
tive groups were small, resulting in only limited power
(<10%) to distinguish the small differences in survival
actually observed between groups here. For the markers
with the highest positivity (ie, 15%) in this study, we had
good (ie, 80%) power to detect only much larger hazard
ratios that were observed here (ie, 3.4 or greater).
Conclusion
While the current study evaluated only protein expression
in relation to survival and not the potential use of these
biomarkers in the early detection of ESCC, the generally
low prevalence of expression positivity indicates that they
would not be suitable candidates for early detection mark-
ers. We were unable to identify a role for biomarkers in
the FasL-Fas apoptotic pathway and prognosis in ESCC.
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